410 related articles for article (PubMed ID: 36185807)
21. Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.
Di Ruscio V; Del Baldo G; Fabozzi F; Vinci M; Cacchione A; de Billy E; Megaro G; Carai A; Mastronuzzi A
Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140466
[TBL] [Abstract][Full Text] [Related]
22. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
[TBL] [Abstract][Full Text] [Related]
23. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
24. CAR T cell therapies for diffuse midline glioma.
Thomas BC; Staudt DE; Douglas AM; Monje M; Vitanza NA; Dun MD
Trends Cancer; 2023 Oct; 9(10):791-804. PubMed ID: 37541803
[TBL] [Abstract][Full Text] [Related]
25. Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
Parekh K; LeBlang S; Nazarian J; Mueller S; Zacharoulis S; Hynynen K; Powlovich L
Neoplasia; 2023 Mar; 37():100876. PubMed ID: 36709715
[TBL] [Abstract][Full Text] [Related]
26. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement.
Valvi S; Manoharan N; Mateos MK; Hassall TE; Ziegler DS; McCowage GB; Dun MD; Eisenstat DD; Gottardo NG; Hansford JR
Med J Aust; 2024 Jun; 220(10):533-538. PubMed ID: 38699949
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
30. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
31. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
32. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
33. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
34. Interdisciplinary care of children with diffuse midline glioma.
Coleman C; Chen K; Lu A; Seashore E; Stoller S; Davis T; Braunstein S; Gupta N; Mueller S
Neoplasia; 2023 Jan; 35():100851. PubMed ID: 36410226
[TBL] [Abstract][Full Text] [Related]
35. Diffuse intrinsic pontine gliomas: treatments and controversies.
Bredlau AL; Korones DN
Adv Cancer Res; 2014; 121():235-259. PubMed ID: 24889533
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
37. Predicting outcome in childhood diffuse midline gliomas using magnetic resonance imaging based texture analysis.
Szychot E; Youssef A; Ganeshan B; Endozo R; Hyare H; Gains J; Mankad K; Shankar A
J Neuroradiol; 2021 Jun; 48(4):243-247. PubMed ID: 32184119
[TBL] [Abstract][Full Text] [Related]
38. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.
Argersinger DP; Rivas SR; Shah AH; Jackson S; Heiss JD
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771443
[TBL] [Abstract][Full Text] [Related]
39. Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.
Kaye EC; Baker JN; Broniscer A
CNS Oncol; 2014 Nov; 3(6):421-31. PubMed ID: 25438813
[TBL] [Abstract][Full Text] [Related]
40. Management of diffuse pontine gliomas in children: recent developments.
Kebudi R; Cakir FB
Paediatr Drugs; 2013 Oct; 15(5):351-62. PubMed ID: 23719782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
